Chronic kidney disease (CKD) is highly prevalent in patients with chronic heart failure (CHF)
and increases the risk of overall and cardiovascular (CV) mortality. Despite evidence …

A worsening renal function is prevalent among patients with cardiovascular disease,
especially heart failure (HF). Sacubitril/valsartan appears to prevent worsening of renal …

Objectives: The purpose of this study was to evaluate the renal effects of sacubitril/valsartan
in patients with heart failure and reduced ejection fraction. Background: Renal function is …

Background Some patients with heart failure may experience transient changes in kidney
function upon transition to sacubitril/valsartan. Whether such changes portend adverse …

Abstract Sacubitril/valsartan (LCZ696) is recommended for ejection fraction reduction in
heart failure. However, studies comparing the effects of sacubitril/valsartan in patients with …

Background Heart failure with reduced ejection fraction (HFrEF) is a chronic disease with
substantial mortality. Management of HFrEF has seen significant breakthrough after the …

Real-life data confirming the favourable renal outcome in patients with heart failure (HF)
treated with Sacubitril/Valsartan, previously found in several trials (RCTs), are still scant. We …

Patients with chronic kidney disease (CKD) are often complicated with heart failure with
preserved ejection fraction (HFpEF). However, several drugs, including angiotensin …

Background Angiotensin receptor and neprilysin inhibition (ARNI) has been shown to
reduce cardiovascular mortality by 20% as compared with enalapril in a randomized …

Background: Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients
with heart failure with reduced ejection fraction, but its effects on kidney function and cardiac …